These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 31612912)

  • 21. FOXM1 is required for small cell lung cancer tumorigenesis and associated with poor clinical prognosis.
    Liang SK; Hsu CC; Song HL; Huang YC; Kuo CW; Yao X; Li CC; Yang HC; Hung YL; Chao SY; Wu SC; Tsai FR; Chen JK; Liao WN; Cheng SC; Tsou TC; Wang IC
    Oncogene; 2021 Jul; 40(30):4847-4858. PubMed ID: 34155349
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer.
    Ross JS; Wang K; Elkadi OR; Tarasen A; Foulke L; Sheehan CE; Otto GA; Palmer G; Yelensky R; Lipson D; Chmielecki J; Ali SM; Elvin J; Morosini D; Miller VA; Stephens PJ
    J Clin Pathol; 2014 Sep; 67(9):772-6. PubMed ID: 24978188
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of circulating tumor DNA using target next-generation sequencing in extensive-stage small-cell lung cancer.
    Zhang J; Zhou N; Deng H; Chen X; Chen Q; Wang Q; Sun L; Wen Y; Cao X; Luo Z; Zhang J; Zhu W; Guo L
    Lung Cancer; 2023 Apr; 178():11-19. PubMed ID: 36758321
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance).
    Augert A; Zhang Q; Bates B; Cui M; Wang X; Wildey G; Dowlati A; MacPherson D
    J Thorac Oncol; 2017 Apr; 12(4):704-713. PubMed ID: 28007623
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inferring the Evolution and Progression of Small-Cell Lung Cancer by Single-Cell Sequencing of Circulating Tumor Cells.
    Su Z; Wang Z; Ni X; Duan J; Gao Y; Zhuo M; Li R; Zhao J; Ma Q; Bai H; Chen H; Wang S; Chen X; An T; Wang Y; Tian Y; Yu J; Wang D; Xie XS; Bai F; Wang J
    Clin Cancer Res; 2019 Aug; 25(16):5049-5060. PubMed ID: 31113842
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic Mutation Analysis in Small Cell Lung Cancer by a Novel NGS-Based Targeted Resequencing Gene Panel and Relation with Clinical Features.
    Jin W; Lei Z; Xu S; Fachen Z; Yixiang Z; Shilei Z; Tao G; Zhe S; Fengzhou L; Su WH; Chundong G
    Biomed Res Int; 2021; 2021():3609028. PubMed ID: 33880365
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multi-region exome sequencing reveals the intratumoral heterogeneity of surgically resected small cell lung cancer.
    Zhou H; Hu Y; Luo R; Zhao Y; Pan H; Ji L; Zhou T; Zhang L; Long H; Fu J; Wen Z; Wang S; Wang X; Lin P; Yang H; Wang J; Song M; Yi X; Yang L; Xia X; Guan Y; Fang W; Yang Y; Hong S; Huang Y; Li P; Zhang Y; Zhou N
    Nat Commun; 2021 Sep; 12(1):5431. PubMed ID: 34521849
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer.
    Lin MW; Su KY; Su TJ; Chang CC; Lin JW; Lee YH; Yu SL; Chen JS; Hsieh MS
    Lung Cancer; 2018 Nov; 125():282-290. PubMed ID: 30429033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High mutations in fatty acid metabolism contribute to a better prognosis of small-cell lung cancer patients treated with chemotherapy.
    Lyu Q; Zhu W; Wei T; Ding W; Cao M; Wang Q; Guo L; Luo P; Zhang J
    Cancer Med; 2021 Nov; 10(21):7863-7876. PubMed ID: 34564955
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinicopathological characteristics of thyroid transcription factor 1-negative small cell lung cancers.
    Iida Y; Masuda S; Nakanishi Y; Shimizu T; Nishimaki H; Takahashi M; Hikichi M; Maruoka S; Gon Y; Takahashi N; Hashimoto S
    Hum Pathol; 2018 Sep; 79():127-134. PubMed ID: 29787820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse.
    Almodovar K; Iams WT; Meador CB; Zhao Z; York S; Horn L; Yan Y; Hernandez J; Chen H; Shyr Y; Lim LP; Raymond CK; Lovly CM
    J Thorac Oncol; 2018 Jan; 13(1):112-123. PubMed ID: 28951314
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comprehensive Next-Generation Sequencing Reveals Novel Predictive Biomarkers of Recurrence and Thoracic Toxicity Risks After Chemoradiation Therapy in Limited Stage Small Cell Lung Cancer.
    Li L; Tang S; Yin JC; Dong L; Yang Z; Liu Y; Ma J; Chang P; Pang J; Bao H; Mu D; Zheng X; Aishajiang R; He K; Zhang S; Ni M; Wu X; Wang X; Shao Y; Wang J; Ge H; Yu J; Yuan S
    Int J Radiat Oncol Biol Phys; 2022 Apr; 112(5):1165-1176. PubMed ID: 34942313
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A microRNA signature predicts survival in early stage small-cell lung cancer treated with surgery and adjuvant chemotherapy.
    Bi N; Cao J; Song Y; Shen J; Liu W; Fan J; He J; Shi Y; Zhang X; Lu N; Zhan Q; Wang L
    PLoS One; 2014; 9(3):e91388. PubMed ID: 24637927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of the Clinical Utility of Circulating Tumor Cells at Different Time Points in Predicting Prognosis of Patients With Small Cell Lung Cancer: A Meta-Analysis.
    Jiang AM; Zheng HR; Liu N; Zhao R; Ma YY; Bai SH; Tian T; Liang X; Ruan ZP; Fu X; Yao Y
    Cancer Control; 2021; 28():10732748211050581. PubMed ID: 34654345
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic factors for survival in extensive stage small cell lung cancer (ED-SCLC): the importance of smoking history, socioeconomic and marital statuses, and ethnicity.
    Ou SH; Ziogas A; Zell JA
    J Thorac Oncol; 2009 Jan; 4(1):37-43. PubMed ID: 19096304
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The value of prognostic factors in Chinese patients with small cell lung cancer: A retrospective study of 999 patients.
    Hong X; Xu Q; Yang Z; Wang M; Yang F; Gao Y; Zhou F; Wang L; Liu B; Chen G
    Clin Respir J; 2018 Feb; 12(2):433-447. PubMed ID: 27460525
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical significance of tumor mutation burden and DNA damage repair in advanced stage non-small cell lung cancer patients.
    Zhang H; Deng YM; Chen ZC; Tang YC; Yang S; Zhang SD; Liang JM; Wang YG; Wu X; Zhang RW; Feng WN
    Eur Rev Med Pharmacol Sci; 2020 Jul; 24(14):7664-7672. PubMed ID: 32744692
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical significance of NQO1 polymorphism and expression of p53, SOD2, PARP1 in limited-stage small cell lung cancer.
    Kim HC; Song JS; Lee JC; Lee DH; Kim SW; Lee JS; Kim WS; Rho JK; Kim SY; Choi CM
    Int J Clin Exp Pathol; 2014; 7(10):6743-51. PubMed ID: 25400754
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC.
    Park S; Lee H; Lee B; Lee SH; Sun JM; Park WY; Ahn JS; Ahn MJ; Park K
    J Thorac Oncol; 2019 Sep; 14(9):1640-1650. PubMed ID: 31125737
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer.
    Park JS; Lee JS; Kim EY; Jung JY; Kim SK; Chang J; Kim DJ; Lee CY; Jung I; Kim JH; Kim HR; Moon YW; Kim HS; Cho BC; Shim HS
    Lung Cancer; 2015 Jun; 88(3):325-31. PubMed ID: 25819384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.